Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Finished Goods (2022 - 2025)

Historic Finished Goods for Gyre Therapeutics (GYRE) over the last 4 years, with Q3 2025 value amounting to $3.3 million.

  • Gyre Therapeutics' Finished Goods rose 8419.3% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 8419.3%. This contributed to the annual value of $2.6 million for FY2024, which is 9150.18% up from last year.
  • Gyre Therapeutics' Finished Goods amounted to $3.3 million in Q3 2025, which was up 8419.3% from $3.4 million recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' Finished Goods peaked at $3.4 million during Q2 2025, and registered a low of $1.4 million during Q4 2023.
  • Moreover, its 4-year median value for Finished Goods was $1.8 million (2024), whereas its average is $2.3 million.
  • Its Finished Goods has fluctuated over the past 5 years, first crashed by 243.03% in 2023, then skyrocketed by 12276.84% in 2025.
  • Gyre Therapeutics' Finished Goods (Quarter) stood at $1.4 million in 2022, then decreased by 2.43% to $1.4 million in 2023, then surged by 91.5% to $2.6 million in 2024, then rose by 27.05% to $3.3 million in 2025.
  • Its Finished Goods stands at $3.3 million for Q3 2025, versus $3.4 million for Q2 2025 and $3.3 million for Q1 2025.